Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?

Because of the lack of significant disease-modifying drugs for neurodegenerative disorders, a pressing need for new chemical entities endowed with IMAO-B still exists. Within this framework, and for the first time, a study was performed to compare coumarin- and chomone-3-phenylcarboxamide scaffolds. Compounds <b>10a</b> and <b>10b</b> were the most potent, selective, and reversible noncompetitive IMAO-B. The benzopyrone sp² oxygen atom was found to be position independent and a productive contributor for the ligand–enzyme complex stability